Highlights Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Delayed London S.E. Other stock markets 12:13:28 14/06/2024 BST			5-day change	1st Jan Change
13.73 ^GBX	+0.59%		-0.15%	+51.71%

05-01	Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	MT
05-01	Poolbeg Pharma celebrates full patent approval for Immunomodulator II	AN

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Poolbeg Pharma Secures Full Patent in US for Immunomodulator II	05-01	MT
Poolbeg Pharma celebrates full patent approval for Immunomodulator II	05-01	AN
Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application	05-01	CI
Poolbeg Pharma Signs Option Deal to Buy Orphan Drug Candidate from Silk Road Therapeutics	04-30	MT
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	04-30	AN
Earnings Flash (POLB.L) POOLBEG PHARMA Posts FY23 Loss GBX-0.79	04-30	MT
Poolbeg Pharma PLC Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake	03-20	AN
Poolbeg Pharma plc Announces POLB 001 US Patent Update	03-20	CI
Diversified Energy offers dividend alternative	02-15	AN
Katoro Gold launches fundraising, eyes board shake-up	02-12	AN
Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome	02-12	CI
Poolbeg Pharma hails POLB 001'S potential to treat CRS	01-17	AN
Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome	01-17	CI
K3 Business says cash balances ahead of forecast	12-20	AN
Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully	12-20	CI
Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001	12-11	CI
Poolbeg hails approval; EDX links with Thermo Fisher	11-21	AN
Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme	26/10/23	CI
Poolbeg Pharma Enters Partnership to Develop Metabolic Condition Treatment	17/10/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Poolbeg Pharma PLC

Equities

POLB

GB00BKPG7Z60

Highlights

Filters